Legal & General Group PLC Relmada Therapeutics, Inc. Transaction History

Legal & General Group PLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$2.17 - $35.84 $12,648 - $208,911	-5,829 Reduced 65.47%	3,074 $10,000
Q3 2022 Nov 14, 2022	BUY	$18.3 - $37.02 $22,399 - $45,312	1,224 Added 15.94%	8,903 $329,000
Q2 2022 Aug 22, 2022	SELL	$16.5 - $30.34 $2,013 - $3,701	-122 Reduced 1.56%	7,679 $145,000
Q1 2022 May 16, 2022	BUY	$16.72 - $26.99 $17,271 - $27,880	1,033 Added 15.26%	7,801 $211,000
Q4 2021 Feb 14, 2022	BUY	$16.93 - $26.82 $40,242 - $63,751	2,377 Added 54.13%	6,768 $153,000
Q3 2021 Nov 15, 2021	BUY	$21.86 - $34.77 $48,769 - $77,571	2,231 Added 103.29%	4,391 $115,000
Q1 2021 May 17, 2021	SELL	$31.52 - $39.28 $2,899 - $3,613	-92 Reduced 4.09%	2,160 $76,000
Q3 2020 Nov 13, 2020	SELL	$34.42 - $43.78 $20,066 - $25,523	-583 Reduced 20.56%	2,252 $84,000
Q2 2020 Aug 14, 2020	BUY	$31.59 - $49.98 $89,557 - $141,693	2,835 New	2,835 $127,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.